The contract sales and marketing business will reach $5.2bn (€4bn)
by 2011, as it represents an ideal outsourcing opportunity for
pharma companies competing in this fast growing sector, according
to new market research.
Chemicals company Rhodia has played down reports in the French
press that it is considering a sell-off of its activities in
silicon, food additives and phosphates as part of an asset
divestment programme aimed at improving its profitability.